<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T3" position="float">
 <label>Table 3</label>
 <caption>
  <p>SARS-CoV-2 candidate vaccines in clinical evaluation (July 20, 2020).</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine, sponsor/enrollment age</bold>
    </th>
    <th valign="top" align="center" rowspan="1" colspan="1">
     <bold>Study identifier number (phase, country/estimated first results)</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vector-based vaccines</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">ChAdOx1 nCoV-19 (Oxford University); genetically altered adenovirus expressing the SARS-CoV-2 spike protein/18 to 55 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">ISRCTN89951424 (ph 3, Brazil)/July, 2021NCT04324606 (ph 1-2, United Kingdom)/May, 2021</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Ad5-nCoV (Beijing Institute of Biotechnology, CanSino Biologics Inc); adenovirus type-5 vectored vaccine expressing SARS-CoV-2 full-length spike protein/18 to 60 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04341389 (ph 2, China)/January, 2021NCT04313127 (ph 1, China)/December, 2020</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Gam-COVID-Vac (Gamaleya Research Institute, Health Ministry of the Russian Federation); adenoviral-based vaccine/18 to 60 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04436471 (ph 1, Russian Federation/August, 2020</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Gam-COVID-Vac Lyo (Gamaleya Research Institute, Health Ministry of the Russian Federation/Accellena Research); lyophilizate adenoviral-based vaccine/18 to 60 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04437875 (Phase 1-2, Russian Federation/August, 2020</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">LV-SMENP-DC vaccine (Shenzhen Geno-Immune Medical Institute); lentiviral vector system (NHP/TYF) expressing viral proteins and immune modulatory genes to modify dendritic cells (DCs) and to activate T cells/6 months to 80 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04276896
     <break/>(DC vaccine + LV-SMENP-DC) (ph 1-2, China)/July, 2023
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 aAPC Vaccine (Shenzhen Geno-Immune Medical Institute); NHP/TYF expressing viral proteins and modified artificial antigen-presenting cell (APC) to reactivate T cells/6 months to 80 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04299724 (ph 1, China)
     <break/>/July, 2023
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Nucleic acid vaccines</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273 (NIAID); lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine encoding full-length, spike protein of SARS-CoV-2/18 to 99 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04283461 (ph 1, SUA)
     <break/>/November, 2021
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273 (mRNA-1273 + Placebo) (Moderna TX Inc, Biomedical Advanced Research and Development Authority); two dose levels of mRNA-1273 versus placebo/18 years and older</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04405076 (ph 2-3, SUA)
     <break/>/March, 2021
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">BNT162, (BioNTech Pharmaceuticals GmbH); Dose-Escalation Trial 
     <bold>of</bold> four RNA vaccine candidates combined with a lipid nanoparticle formulation (LNP) (different dosing regimens)/18 to 55 years
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04380701 (ph 1-2, Germany)
     <break/>/August, 2020
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">BNT162 (BioNTech, Pfizer); LNP-mRNAs (different dosing regimens)/18 to 85 years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04368728 (ph 1-2, SUA, Germany)/June, 2021</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">INO-4800 + electroporation using CELLECTRA 2000 (Inovio Pharmaceuticals, CEPI);DNA plasmid encoding S protein delivered by electroporation with CELLECTRA
     <sup>Â®</sup> 2000)/intradermal DNA vaccine/18 years and older
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04336410 (ph 1 SUA, ph 2 USA)/July 2021</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">INO-4800 +electroporation using CELLECTRA 2000 (International Vaccine Institute, CEPI, Inovio Pharmaceuticals)/19 to 64 Year</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04447781 (ph1-2, Republic of Korea)/February 2022</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">GX-19 (Genexine,Inc); DNA vaccine expressing SARS-CoV-2 S-protein antigen/18 to 50 Years</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04445389 (ph1-2, Republic of Korea/March, 2021</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>Resources: U.S. National Library of Medicine 
   <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov</uri> International Clinical Trials Registry Platform (ICTRP)
   <bold>/</bold>
   <uri xlink:type="simple" xlink:href="https://www.isrctn.com/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.isrctn.com/</uri>.
  </p>
 </table-wrap-foot>
</table-wrap>
